Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr;38(2):142-150.
doi: 10.1007/s10930-019-09820-z.

A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance

Affiliations

A Synergistic Combination Against Chronic Myeloid Leukemia: An Intra-molecular Mechanism of Communication in BCR-ABL1 Resistance

Ahmed A El Rashedy et al. Protein J. 2019 Apr.

Abstract

The constitutive BCR-ABL1 active protein fusion has been identified as the main cause of chronic myeloid leukemia. The emergence of T334I and D381N point mutations in BCR-ABL1 confer drug resistance. Recent experimental studies show a synergistic effect in suppressing this resistance when Nilotinib and Asciminib are co-administered to target both the catalytic and allosteric binding site of BCR-ABL1 oncoprotein, respectively. However, the structural mechanism by which this synergistic effect occurs has not been clearly elucidated. To obtain insight into the observed synergistic effect, molecular dynamics simulations have been employed to investigate the inhibitory mechanism as well as the structural dynamics that characterize this effect. Structural dynamic analyses indicate that the synergistic binding effect results in a more compact and stable protein conformation. In addition, binding free energy calculation suggests a dominant energy effect of nilotinib during co-administration. van der Waals energy interactions were observed to be the main energy component driving this synergistic effect. Furthermore, per-residue energy decomposition analysis identified Glu481, Ser453, Ala452, Tyr454, Phe401, Asp400, Met337, Phe336, Ile334, And Val275 as key residues that contribute largely to the synergistic effect. The findings highlighted in this study provide a molecular understanding of the dynamics and mechanisms that mediate the synergistic inhibition in BCR-ABL1 protein in chronic myeloid leukemia treatment.

Keywords: Allosteric inhibitor; Asciminib (ABL001); BCR–ABL1; CML; Molecular dynamics; Mutation; Nilotinib.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Science. 2000 Sep 15;289(5486):1938-42 - PubMed
    1. Cancer Cell. 2002 Aug;2(2):117-25 - PubMed
    1. Cancer J. 2001 Jul-Aug;7 Suppl 1:S14-8 - PubMed
    1. Nature. 2017 Mar 30;543(7647):733-737 - PubMed
    1. IUBMB Life. 2005 Jun;57(6):413-9 - PubMed

Publication types

MeSH terms

LinkOut - more resources